How to Cure Cushing’s Syndrome: Treatments That Work

Curing Cushing’s syndrome depends entirely on what is causing the excess cortisol in the first place. When a pituitary tumor is the source, surgery to remove it achieves remission in roughly 80% of patients at experienced centers. When an adrenal tumor is responsible, removing the affected adrenal gland is often curative. And when the problem is medication-induced, a carefully managed taper of the offending drug can reverse it. The reality, though, is more layered than “find the cause and fix it,” because recurrence is common, recovery is slow, and some of the damage lingers even after cortisol returns to normal.

Pituitary Surgery for Cushing’s Disease

About two-thirds of endogenous Cushing’s syndrome cases stem from a small pituitary tumor that pumps out too much ACTH, the hormone that tells the adrenal glands to produce cortisol. This specific scenario is called Cushing’s disease, and the front-line treatment is transsphenoidal surgery, a procedure where a surgeon reaches the pituitary through the nose and sinuses to remove the tumor.

Results from experienced surgical centers show long-term remission rates averaging around 80% overall, with the figure climbing to about 90% when the tumor is a small, well-defined growth that hasn’t invaded surrounding tissue.¹ Surgical risk is low: mortality is typically under 1% at high-volume centers. One single-center series reported a combined remission rate of about 83% when an immediate repeat operation was offered to patients whose cortisol remained elevated after the first attempt.² Not every center achieves those numbers, however. A 20-year retrospective series from another institution reported an overall remission rate closer to 64%, with a relapse rate of about 23% over a median follow-up of five years.³ That spread in outcomes underscores why guidelines consistently stress that the surgeon’s experience and the center’s volume matter enormously.

Two strong predictors of remission emerge from the data: finding a confirmed adenoma in the tissue removed during surgery, and having surgery for the first time rather than as a repeat procedure.³ Over a 10-year window, roughly one in three patients will ultimately need a second-line treatment because of persistent disease or late relapse.⁴

Adrenal Surgery

When Cushing’s syndrome is caused by a cortisol-producing adrenal tumor, the treatment is straightforward in concept: remove the affected adrenal gland. Laparoscopic adrenalectomy is considered the standard approach. For benign cortisol-secreting adenomas, it is essentially curative, with hormone levels normalizing or improving in virtually all patients in one series followed for up to five years.⁵ Beyond resolving cortisol excess, the metabolic benefits are tangible. In one retrospective cohort, blood pressure, cholesterol, and obesity measures improved within three months of surgery, and diabetes control improved within a year.⁶

Bilateral adrenalectomy, the removal of both adrenal glands, is a different matter. It is sometimes used as a last resort in Cushing’s disease when pituitary surgery, radiation, and medications have all failed. It works rapidly and definitively to eliminate cortisol excess, but it commits the patient to lifelong hormone replacement for both cortisol and aldosterone, because the body has no remaining adrenal tissue. It also carries a significant risk of Nelson’s syndrome, in which the pituitary tumor grows aggressively after the adrenal glands are gone. A systematic review and meta-analysis of over 1,300 patients found that roughly one in four people who undergo bilateral adrenalectomy for Cushing’s disease develops Nelson’s syndrome, and about one in five eventually needs pituitary-directed treatment for it.⁷ The risk may persist for decades after the operation.⁸

Medications for Cushing’s Syndrome

Drug therapy is not usually the first choice for a cure, but it plays several important roles: bridging patients to surgery, controlling cortisol in people who are too sick for an operation, and managing disease that persists or recurs after surgery. The medications fall into a few categories based on where they act.

Steroidogenesis inhibitors block cortisol production at the adrenal gland. The older drugs in this category, ketoconazole and metyrapone, have decades of clinical use behind them and can bring cortisol under control fairly quickly.⁹ Newer agents offer refinements. Osilodrostat, for instance, blocks the enzyme responsible for the final step in cortisol synthesis with greater potency than either metyrapone or ketoconazole in laboratory studies.¹⁰ In pooled clinical data, osilodrostat reduced blood pressure and improved blood sugar control over 72 weeks of treatment. Among patients who started with elevated blood pressure, more than half achieved normal systolic readings by 12 weeks, and in those with elevated blood sugar, most achieved improved glycemic control at 72 weeks.¹¹

Pituitary-directed drugs aim to shrink or quiet the tumor itself. Pasireotide is a somatostatin analog that targets receptors abundant on corticotroph tumors, and combining it with cabergoline, a dopamine agonist, can normalize cortisol in about half of patients. Adding ketoconazole to that combination can push biochemical control rates even higher.¹² The downside is that response varies, some patients escape from the drug’s effect over time, and the side-effect burden can be considerable.¹³

Mifepristone takes a completely different approach. Instead of lowering cortisol levels, it blocks the glucocorticoid receptor so that cortisol cannot act on tissues even when it is present. In a clinical trial of patients with Cushing’s syndrome and diabetes, mifepristone led to meaningful improvements in blood sugar: average fasting glucose dropped substantially, and hemoglobin A1c fell from about 7.4% to about 6.3%.¹⁴ Because it does not lower measurable cortisol, clinicians monitor treatment by tracking clinical signs and metabolic markers rather than cortisol blood tests.

Radiation Therapy

Radiation is typically reserved for Cushing’s disease patients whose pituitary tumors persist or recur after surgery. Stereotactic radiosurgery, which delivers a focused beam to the tumor, has a sizable evidence base. A large international multicenter study reported that cortisol normalized in 80% of patients within 10 years, though the average time to normalization was about 14 and a half months. Recurrence after initial control occurred in about 18% of patients, bringing the rate of durable long-term control down to roughly 64% at 10 years.¹⁵

A meta-analysis focused specifically on patients with recurrent or persistent disease after surgery found biochemical remission in about 67% of cases, achieved in a mean time of about 26 months. Recurrence after radiosurgery-induced remission was documented in about 21% of those patients.¹⁶ The main trade-off is hypopituitarism: roughly a quarter to a third of patients develop new pituitary hormone deficiencies after radiosurgery, requiring lifelong hormone replacement.¹⁷ Because cortisol normalization is gradual, patients usually need medical therapy to control their cortisol during the months or years while the radiation takes full effect.

Steroid-Induced Cushing’s Syndrome

The most common form of Cushing’s syndrome in everyday practice is iatrogenic, meaning it is caused by prescription corticosteroids like prednisone, dexamethasone, or high-dose inhaled steroids. The solution is conceptually simple: stop or reduce the offending medication. In practice, it is anything but simple, because the body’s own cortisol production has been suppressed by the external supply, and stopping abruptly can trigger a life-threatening adrenal crisis.

The standard approach is a gradual taper, stepping the dose down slowly over weeks to months while the adrenal glands wake back up. In one case report, a patient who had developed full-blown Cushing’s from prolonged steroid injections was transitioned to physiological-dose hydrocortisone replacement under endocrinology supervision before being weaned off entirely.¹⁸ When the problem stems from inhaled steroids combined with medications that inhibit their metabolism, options include reducing the inhaler dose, switching to a different steroid, or removing the interacting drug.¹⁹ Throughout the taper, you need monitoring for signs that the adrenal glands have not yet recovered sufficiently to handle physical stress.

Ectopic Cushing’s Syndrome

In about 10% to 15% of endogenous cases, ACTH is being secreted not by a pituitary tumor but by a tumor elsewhere in the body, most often in the lungs, thymus, or pancreas. This is ectopic Cushing’s syndrome, and it poses a distinct challenge because localizing the offending tumor can be extremely difficult. These tumors are sometimes tiny and can hide in unexpected places.²⁰

The best outcome requires finding and surgically removing the source tumor, but in many cases the tumor cannot be found on imaging or cannot be safely resected. When resection is possible, the prognosis depends on the tumor type: a benign bronchial carcinoid caught early is a very different situation from a metastatic small-cell lung cancer. When the tumor cannot be removed, the focus shifts to cortisol control through steroidogenesis inhibitors, and in some cases bilateral adrenalectomy as a salvage measure. A methodical approach that combines prompt diagnosis, cortisol control, and resection when feasible gives the best results.²¹

The Rocky Road After a Cure

One of the most underappreciated aspects of Cushing’s treatment is that “cure” does not mean you feel better right away. After successful surgery, cortisol levels plummet, and for many patients the weeks and months that follow are genuinely miserable. Glucocorticoid withdrawal syndrome is a direct consequence of the body having adapted to chronically high cortisol: once those levels fall, tissues that became dependent on the excess are suddenly starved. Symptoms include crushing fatigue, muscle and joint pain, nausea, headaches, insomnia, mood swings, and sometimes fever.²²

What makes this period especially tricky is that withdrawal symptoms overlap heavily with adrenal insufficiency and even with recurrence of Cushing’s itself. Clinicians have to distinguish between three very different problems that can look nearly identical. Patients typically need replacement hydrocortisone during the recovery period, and the dose is gradually tapered over months as the body’s cortisol axis recovers. That axis recovery requires both clinical and biochemical monitoring.²³ Paradoxically, some patients develop withdrawal symptoms even when lab tests suggest their cortisol axis is working again, a phenomenon thought to reflect lasting changes in how tissues respond to normal cortisol levels.²²

Monitoring for Recurrence

Even after cortisol normalizes, the story is not over. Recurrence rates in Cushing’s disease are high enough that lifelong monitoring is widely recommended. Reported relapse rates range from 3% to nearly 50%, with average time to recurrence anywhere from about one to four years.²⁴

How aggressive the monitoring should be depends partly on the cortisol level right after surgery. Patients whose cortisol drops very low in the first days after the operation have a better near-term prognosis, but even a very low nadir does not guarantee against late relapse.²⁵ Patients whose first postoperative cortisol remains elevated are at substantially higher risk. One study found that patients with a nadir cortisol at or above a certain threshold were more than six times as likely to recur.²⁶ A proposed monitoring protocol recommends twice-yearly testing for the first three years after surgery, then annual testing thereafter for those whose cortisol drops appropriately, and more frequent evaluation for those with borderline postoperative cortisol.²⁴

What Recovers After Treatment and What Does Not

Even when cortisol is controlled for good, many patients find that some of the damage from Cushing’s persists. Quality of life improves after treatment, but it does not fully normalize. A systematic review found that while every measured aspect of quality of life and cognitive functioning improved after treatment, patients still scored lower than healthy controls on all domains.²⁷ Fatigue, anxiety, and depression are especially persistent. Patients with long-term biochemical cure of Cushing’s disease still report worse scores on fatigue and mood scales compared to the general population, particularly when hypopituitarism develops as a consequence of treatment.²⁸

Mental health deserves specific attention. Depression that develops during active Cushing’s often improves once cortisol normalizes, and cortisol-lowering drugs themselves can relieve depressive symptoms. But prolonged exposure to high cortisol can cause lasting psychological changes, meaning some patients continue to need treatment even after the biochemical problem is resolved. Cognitive-behavioral therapy and antidepressant medications both have roles in the long-term psychiatric management of these patients.²⁹ Complete psychiatric recovery is not guaranteed.³⁰

Bone health, by contrast, is an area where the news is more encouraging. Cushing’s weakens bones, but treatment reverses the trend. In a two-year follow-up study, about four in five patients showed improved bone density after successful treatment, with the spine recovering faster than the hip. No clinical fractures occurred during that period.³¹ Longer-term data show that bone density continues to improve for up to 20 years after treatment, and fracture rates, which peak in the two years before diagnosis, drop steadily once cortisol is controlled.³²

Cushing’s Syndrome in Children

Children with Cushing’s disease face one concern that adults do not: growth suppression. Excess cortisol inhibits growth, and at diagnosis, children typically have heights well below what is expected for their age. The encouraging finding is that growth catches up after treatment. A single-center study followed children for a mean of about seven years after definitive treatment and found that their height scores improved, though many still fell somewhat below their genetic target.³³

Growth hormone deficiency after treatment is common in children, because surgery or radiation to the pituitary can damage the cells that produce growth hormone. Early replacement with growth hormone injections appears to contribute to better final height outcomes. In one long-term study, children who received growth hormone replacement showed significant height improvements, and the gap between their final height and their genetic target narrowed compared to what it had been at diagnosis.³⁴

Cushing’s Syndrome in Pregnancy

Fewer than 200 cases of Cushing’s syndrome in pregnancy have been reported in the medical literature, making it extraordinarily rare and poorly standardized. Diagnosis is complicated by the fact that normal pregnancy raises cortisol levels two- to threefold, and common pregnancy complaints like weight gain, stretch marks, and high blood pressure overlap with Cushing’s symptoms. Interestingly, the most common cause in pregnancy is an adrenal adenoma rather than a pituitary tumor, which is the reverse of what is seen in the general population.³⁵

Active Cushing’s during pregnancy carries high stakes: maternal complications like severe hypertension, preeclampsia, and diabetes, along with fetal risks including premature birth and growth restriction. Management is highly individualized. Surgery, when needed, is safest during the second trimester. Metyrapone has been used to control cortisol during pregnancy, though it carries a risk of worsening blood pressure. Other cortisol-lowering drugs are generally avoided due to limited safety data or teratogenic concerns. Cabergoline may be an alternative in some cases. Milder presentations can sometimes be managed conservatively by treating the individual complications until the pregnancy is complete.³⁶ Every decision in this setting involves a careful weighing of maternal and fetal risk by a team that includes endocrinology, obstetrics, and often surgery.³⁷

1
PubMed. Transsphenoidal surgery for Cushing’s disease: a review of success rates, remission predictors, management of failed surgery, and Nelson’s Syndrome
2
PubMed. Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing’s disease, the role of cortisol, ACTH assessment and immediate reoperation
3
PubMed. Prediction of remission and recurrence of Cushing’s disease following transsphenoidal surgery (TSS): a single center, 20-year, retrospective series
4
PubMed Central. The Treatment of Cushing’s Disease
5
PubMed. Laparoscopic adrenalectomy by the anterior transperitoneal approach: results of 108 operations in unselected cases
6
PubMed Central. Cardiovascular risk improvement after laparoscopic adrenalectomy in patients with cortisol-secreting adrenal adenoma, a retrospective cohort study
7
PubMed Central. Prevalence of Nelson’s syndrome after bilateral adrenalectomy in patients with cushing’s disease: a systematic review and meta-analysis
8
PubMed. Nelson’s syndrome after bilateral adrenalectomy for Cushing’s disease
9
PubMed Central. Cushing’s disease: adrenal steroidogenesis inhibitors
10
PubMed. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study
11
PubMed Central. Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
12
PubMed Central. Clinical use of pasireotide for Cushing’s disease in adults
13
The Journal of Clinical Endocrinology & Metabolism. Tumor-Directed Therapeutic Targets in Cushing Disease
14
The Journal of Clinical Endocrinology & Metabolism. Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing’s Syndrome
15
The Journal of Clinical Endocrinology & Metabolism. Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study
16
PubMed. Radiosurgery in recurrent and persistent Cushing’s Disease: a Systematic Review and Meta-Analysis
17
PubMed Central. Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience
18
PubMed Central. A rare case report of iatrogenic Cushing syndrome with multisystem involvement due to prolonged steroid injections: a diagnostic challenge
19
PubMed Central. Inhalational Steroids and Iatrogenic Cushing’s Syndrome
20
PubMed Central. Recognition and Management of Ectopic ACTH Secreting Tumors
21
PubMed. A clinical perspective on ectopic Cushing’s syndrome
22
European Journal of Endocrinology. Potential mechanisms of the glucocorticoid withdrawal syndrome
23
PubMed Central. Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
24
PubMed Central. Detection of recurrent Cushing’s disease: proposal for standardized patient monitoring following transsphenoidal surgery
25
PubMed Central. Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing’s disease
26
PubMed. Postoperative Serum Cortisol and Cushing Disease Recurrence in Patients With Corticotroph Adenomas
27
The Journal of Clinical Endocrinology & Metabolism. Improvement but No Normalization of Quality of Life and Cognitive Functioning After Treatment of Cushing Syndrome
28
The Journal of Clinical Endocrinology & Metabolism. Quality of Life in Patients after Long-Term Biochemical Cure of Cushing’s Disease
29
PubMed. Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment
30
PubMed. Psychiatric Symptoms in Patients with Cushing’s Syndrome: Prevalence, Diagnosis and Management
31
Journal of Bone and Mineral Research. The Effect of Biochemical Remission on Bone Metabolism in Cushing’s Syndrome: A 2‐Year Follow‐Up Study
32
European Journal of Endocrinology. Persistent improvement of bone mineral density up to 20 years after treatment of Cushing’s syndrome
33
PubMed Central. Long-term outcomes of children treated for Cushing’s disease: a single center experience
34
PubMed. Linear growth and final height after treatment for Cushing’s disease in childhood
35
European Journal of Endocrinology. MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushing’s syndrome during pregnancy: solved and unsolved questions
36
PubMed Central. The diagnosis and management of Cushing’s syndrome in pregnancy
37
PubMed. The medical management of Cushing’s syndrome during pregnancy